Factors influencing pharmaceutical companies’ decisions to pursue compassionate use programs in the EU: a qualitative study in The Netherlands

The decision to pursue CUPs is influenced by multiple factors, with regulatory uncertainties and operational complexities playing significant roles. Improving clarity concerning CUP regulations, particularly data collection and the post-marketing phase, could encourage more pharmaceutical companies to apply for CUPs, which would provide patients with earlier access to potentially promising treatments.